ImmunoGen Inc.
About ImmunoGen Inc.
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is being advanced to Phase 3 testing for FRα-positive platinum-resistant ovarian cancer, and is also in Phase 1b/2 testing in combination regimens for earlier-stage disease. The Company's ADC technology is used in three other clinical-stage ImmunoGen product candidates, in Roche's marketed product, Kadcyla®, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda.
639 articles about ImmunoGen Inc.
-
ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2012 Financial Results and Provides Quarterly Update
4/27/2012
-
ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2012 Financial Results
4/19/2012
-
ImmunoGen, Inc. Initiates Phase I Trial in Non-Hodgkin’s Lymphoma with Its Novel IMGN529 Anticancer Compound
4/17/2012
-
ImmunoGen, Inc. Announces the IND Is Now Active for Its Folate-Receptor Targeting Anticancer Compound, IMGN853
4/17/2012
-
ImmunoGen, Inc. Announces Initiation of Phase II Evaluation of Its IMGN901 Product Candidate
3/30/2012
-
ImmunoGen, Inc. Announces Conference Call at 8:00 am ET March 30, 2012 to Discuss Today's Favorable Announcements about Trastuzumab Emtansine (T-DM1) and About IMGN901
3/30/2012
-
ImmunoGen, Inc. Announces Webcast of Presentation at the Cowen and Company 32nd Annual Health Care Conference
3/5/2012
-
ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
2/7/2012
-
ImmunoGen, Inc. Announces Addition of Kristine Peterson and Dean Mitchell to Its Board of Directors
1/30/2012
-
ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2012 Financial Results and Provides Quarterly Update
1/27/2012
-
ImmunoGen, Inc. Announces Webcast of Presentation at the J.P. Morgan 30th Annual Healthcare Conference
1/4/2012
-
ImmunoGen, Inc. Announces Antibody-Drug Conjugate Collaboration With Eli Lilly and Company Worth Up to $200 Million
12/20/2011
-
ImmunoGen, Inc. Announces Webcast of Presentation at the Oppenheimer 22nd Annual Healthcare Conference
12/6/2011
-
ImmunoGen, Inc. Earns Milestone Payment From Amgen With IND Achievement for Second TAP Compound
11/14/2011
-
ImmunoGen, Inc. Named One of The Boston Globe's 2011 Top Places to Work
11/7/2011
-
ImmunoGen, Inc. Earns Milestone From Amgen With IND Achievement
11/3/2011
-
ImmunoGen, Inc. Reports First Quarter Fiscal Year 2012 Financial Results and Provides Quarterly Update
10/28/2011
-
ImmunoGen, Inc. Earns Milestone With Start of SAR3419 Phase II Testing
10/20/2011
-
ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2012 Financial Results
10/20/2011
-
ImmunoGen, Inc. Announces Submission of IND for Wholly Owned Product Candidate for Non-Hodgkin's Lymphoma
9/23/2011